Collaborative European Effort to
Develop Diabetes Diagnostics

The primary aim of CEED3 is to develop diagnostic tools to differentiate specific subgroups of
diabetic patients to allow individualisation of patient care This will be achieved through integrating expertise and complementary approaches from leading European groups working in the fields of beta-cell biology, biomarker discovery and diabetes genetics with clinical medicine. The development of diabetes diagnostic tools will involve a clearly defined process of discovery of potential novel genetic and non-genetic biomarkers, validation within test and population based data samples, development of a clinical application and then dissemination of this application. The diagnostic tools will be to:

1. identify patients with specific subgroups of monogenic diabetes;
2. to recognise non diabetic and diabetic subjects with initial pancreatic beta-cell dysfunction at high risk of rapidly deteriorating glycaemia; and
3. the detection of diabetic patients at increased risk of vascular complications.

In all of these clinical areas the ability to diagnose specific subgroups of diabetic patients will alter treatment and management. We therefore believe that in the time of this proposal it will be possible to develop tools that can guide the individualisation of therapy and that have a direct benefit for patient care.

Publications

for a list of relevant reviews, papers and guidelines resulting from this research see: http://www.metabol.cm-uj.krakow.pl/ceed3/eng/professionals/professional.htm